Please assess the completion status of the following clinical trial:

Trial Title: Lacosamide IV and EEG/EKG (LIVE) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.~2. Adult patients 18-65 years~3. Diagnosis of focal epilepsy~4. Continuous EEG and video monitoring~5. Continuous EKG~6. Active EEG showing frequent spikes, electrographic or clinical seizures~Exclusion Criteria:~1. Subject has no IV access.~2. Subject is hemodynamically unstable.~3. Previous use of Lacosamide~4. Primary generalized epilepsy~5. Non-epileptic seizures~6. No significant cardiac, renal or hepatic disease~7. No cardiac arrhythmias including heart block~8. Subject is a pregnant or lactating woman.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 100 mg IV (Type: OTHER): 100 mg IV lacosamide infused over 30 minutes
- 200 mg IV (Type: OTHER): 200 mg IV lacosamide infused over 30 minutes
- 400 mg IV (Type: OTHER): 400 mg IV lacosamide infused over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).